Inclusion Criteria:

- Signed, informed consent.

- Patients with AML, MDS (subtype RAEB-1 or RAEB-2), or MM whose disease has relapsed
or is refractory to front line and/ or salvage therapy; elderly patients (≥ 60 years)
with AML, MDS, MM who are not candidates for chemotherapy and for whom other therapy
is inappropriate.

- Patients should have recovered from the acute adverse effects of prior therapies
(excluding alopecia and grade II neuropathy).

- AML, MDS and MM are diseases of the haematopoietic system and can cause
myelosuppression. Consequently supportive therapy should be given to ensure adequate
values, according to local guidelines.

- A bone marrow aspirate/ biopsy performed within four weeks prior to study entry.

- Adequate bone marrow, hepatic and renal function including the following:

1. Patients with high blast counts can be included in the trial, if they can be
controlled by the use of hydroxyurea (500-3000 mg daily).

2. Total bilirubin ≤ 1.5 x upper normal limit.

3. AST (SGOT), ALT (SGPT) ≤ 2.5 x upper normal limit.

4. Creatinine ≤1.5 x upper normal limit.

- Age ≥ 18 years

- Performance status (PS) ≤ 2 (ECOG scale).

- Estimated life-expectancy greater than 3 months.

- Female patients with reproductive potential must have a negative serum pregnancy test
within 7 days prior to the start of the trial. A woman with reproductive potential is
defined as one who is biologically capable of becoming pregnant. Patients who are not
surgically sterile or postmenopausal must agree to use a medically acceptable and
highly effective method of birth control for the duration of the study and to
continue after the end of CHR-2797 treatment for a further 3 months (female patients)
or for a further 6 months (for male patients and their partners). A highly effective
method of birth control is defined as any method that results in a low failure rate,
including implants, injectables, some intra-uterine devices (IUD's), sexual
abstinence, and vasectomy/ sterilization. Sexually active males and females using
oral contraceptive pills should also use barrier contraception. Although there is no
reason to believe that the use of CHR-2797 has an effect on the pharmacokinetics of
hormonal contraceptives, this has not yet been proven.

Exclusion Criteria:

- Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy,
immunotherapy or use of other investigational agents within the 4 weeks prior to
trial entry- except for hydroxyurea (maximum daily dose is 3 g).

- Indolent, smouldering myeloma, monoclonal gammopathy with unknown significance.

- Patients who need a daily dose of hydroxyurea greater than 3 g to control
leukocytosis.

- Co-existing active infection or serious concurrent illness.

- Any co-existing medical condition that in the investigator's judgement will
substantially increase the risk associated with the patient's participation in the
study

- Psychiatric disorders or altered mental status precluding understanding of the
informed consent process and/or completion of the necessary studies.

- Gastrointestinal disorders that may interfere with absorption of the study drug.

- Patients with platelet count(s) < 20,000.

- Patients who have had a blood transfusion (platelet support or packed cells) within 7
days prior to study entry.

- Persistent grade II or greater toxicity from any cause (except haematological
toxicities and peripheral neuropathy).

- Patients with grade III-IV peripheral neuropathy.

- Pregnant or breast-feeding women.